000 02443nam  2200421zi 4500
0019.934797
003CaOODSP
00520240410112705
006m     o  d f      
007cr mn|||||||||
008240301e20240308onc     ob   f000 0 eng d
020 |a9780660705675|q(report)
020 |a9780660705682|q(summary)
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aHP40-352/1-2024E-PDF
0861 |aHP40-352/2-2024E-PDF
24500|aUpdated guidance on the use of protein subunit COVID-19 vaccine (Novavax Nuvaxovid).
264 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cMarch 8, 2024.
264 4|c©2024
300 |a1 online resource (12 pages, 3 unnumbered pages) + |e1 summary (4 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aCover title.
500 |aIssued also in French under title: Mise à jour des directives sur l'utilisation du vaccin à sous-unités protéiques contre la COVID-19 (Nuvaxovid de Novavax).
500 |aAt head of title: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).
500 |aPub.: 230829 (report). Pub.: 230831 (summary).
504 |aIncludes bibliographical references.
650 0|aCOVID-19 vaccines|zCanada.
7102 |aPublic Health Agency of Canada, |eissuing body.
7101 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body.
77508|tMise à jour des directives sur l'utilisation du vaccin à sous-unités protéiques contre la COVID-19 (Nuvaxovid de Novavax).|w(CaOODSP)9.934798
85640|qPDF|s638 KB|uhttps://publications.gc.ca/collections/collection_2024/aspc-phac/HP40-352-1-2024-eng.pdf|zReport
85640|qPDF|s485 KB|uhttps://publications.gc.ca/collections/collection_2024/aspc-phac/HP40-352-2-2024-eng.pdf|zSummary
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-updated-guidance-use-protein-subunit-covid-19-vaccine-novavax-nuvaxovid.html|zReport
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-updated-guidance-use-protein-subunit-covid-19-vaccine-novavax-nuvaxovid.html|zSummary